現在価格
Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. The company is headqua...|
e.g. Promoter holding
Loading chart...
アナリストによるEPSおよび売上高の予想コンセンサス。
この企業の業績予想は利用できません。
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | TTRADESTATI... | TRAD | $147.69M | 126.12 | 1.27 | — | — | — | — |
| 2. | TTRADESTATI... | TRAD | $147.69M | 126.12 | 1.27 | — | — | — | — |
| 3. | AAperture A... | APUR | $148.37M | — | — | — | — | — | — |
| 4. | NSouthern C... | NCO | $146.85M | — | — | — | — | — | — |
| 5. | XXFLH Capit... | XFLH | $146.33M | — | — | — | — | — | — |
連結数値(百万円)/単体表示可
| Quarter (M) | Sep 21 | Dec 21 | Mar 22 | Jun 22 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 |
Gross Profit % | - | - | - | - |
| 0 | 0 | 0.49 | 0.52 | |
EBIT | 0 | 0 | -0.49 | -0.52 |
OPM % | - | - | - | - |
Non-Operating Income | 0 | 0 | -0.01 | -0.02 |
PBT | 0 | 0 | -0.5 | -0.54 |
Income Tax | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - |
Net Income | 0 | 0 | -0.5 | -0.54 |
NPM % | - | - | - | - |
連結数値(百万円)/単体表示可
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 |
|---|---|---|---|
Revenue | 0 | 0 | 0 |
COGS | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 |
Gross Profit % | - | - | - |
| 0 | 1.67 | 0.9 | |
EBIT | 0 | -1.67 | -0.9 |
OPM % | - | - | - |
Non-Operating Income | 0 | -0.03 | -0.05 |
PBT | 0 | -1.7 | -0.96 |
Income Tax | 0 | 0 | 0 |
Tax Rate % | - | - | - |
Net Income | 0 | -1.7 | -0.96 |
NPM % | - | - | - |
連結数値(百万円)/単体表示可
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 |
|---|---|---|---|
| 0 | 0.02 | 0.04 | |
| 0 | 0 | 0 | |
| 0 | 0 | 0 | |
| 1.3 | 0.04 | 0.11 | |
| 0 | 0 | 0 | |
Total Assets | 0 | 0.06 | 0.15 |
| 0 | 0 | 0 | |
| -2.29 | -1.07 | -0.74 | |
| 0 | 0.8 | 0.2 | |
| 0.66 | 0 | 0.5 | |
| 0 | 0.33 | 0.19 | |
Total Liabilities | 0 | 0.06 | 0.15 |
連結数値(百万円)/単体表示可
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 |
|---|---|---|---|
| -1.62 | -2.07 | -0.28 | |
| 0 | 0 | 0 | |
| 2.92 | 0.8 | 0.3 | |
Net CFNet Cash Flow | 1.29 | -1.27 | 0.02 |
FCFFree Cash Flow | -1.62 | -2.07 | -0.28 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2019 | Dec 2020 | Dec 2021 |
|---|---|---|---|
| - | - | 105.6% | |
| - | -0.56 | -0.27 | |
| 1.95 | 0.12 | 0.22 | |
| - | - | 0.00 | |
Cash Conversion | - | 1.22 | 0.29 |
Payout Ratio | - | - | - |
| - | - | - | |
| - | - | - | |
| - | - | - | |
| 1.00 | 1.00 | 5.00 | |
| - | - | - | |
| - | - | - | |
| - | - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Alpex Acquisition Corp - Class Aの株主構成(SEC提出書類より)
Shares sold short · updated twice a month
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 30 Oct 2026 | 733 | -99.1% | 1.00 | |
| 15 Oct 2026 | 80,484 | +62290.7% | 2.10 | |
| 30 Sep 2026 | 129 | -79.1% | 1.00 | |
| 15 Sep 2026 | 616 | -28.3% | 1.00 | |
| 31 Aug 2026 | 859 | +813.8% | 1.00 | |
| 14 Aug 2026 | 94 | +118.6% | 1.00 | |
| 31 Jul 2026 | 43 | -99.9% | 1.00 | |
| 15 Jul 2026 | 32,063 | 1.00 |
FINRA consolidated short interest, reported twice a month for every US listing.
Alpex Acquisition Corp - Class AのSEC提出書類と決算説明会の議事録
What recent news says about Alpex Acquisition Corp - Class A, scored for sentiment.